{
    "clinical_study": {
        "@rank": "109382", 
        "arm_group": [
            {
                "arm_group_label": "Low Strength BBI-4000 and Vehicle", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High Strength BBI-4000 and Vehicle", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, pharmacokinetics and\n      treatment effect of BBI-4000 when topically applied to subjects with axillary hyperhidrosis."
        }, 
        "brief_title": "A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis", 
        "condition": "Hyperhidrosis", 
        "condition_browse": {
            "mesh_term": "Hyperhidrosis"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, vehicle controlled, double blind study in subjects with axillary\n      hyperhidrosis designed to assess the safety, tolerability and the effect on sweat production\n      of topically applied BBI-4000 for 14 days.\n\n      Safety will be assessed though vital signs, physical exam, adverse events, local skin\n      reactions and laboratory tests (blood chemistry and hematology).\n\n      Efficacy will be assessed though the gravimetrically measured sweat production and the\n      Hyperhidrosis Disease Severity Score (HDSS).\n\n      Pharmacokinetic information will also be collected."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or Female subjects from 18 to 45 years of age in good general health.\n\n          -  Primary axillary hyperhidrosis of at least 6 months duration.\n\n          -  Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.\n\n          -  Gravimetric test at baseline indicating at least 100mg of axillary sweat production\n             in a 5 min period.\n\n          -  Use of a medically appropriate contraceptive method.\n\n        Exclusion Criteria:\n\n          -  Prior axillary use of botulinum toxin within 2 years of study entry.\n\n          -  Prior iontophoresis treatment for axillary hyperhidrosis within 12 weeks of study\n             entry.\n\n          -  Prior surgical procedures for hyperhidrosis or surgical procedures in the axillary\n             areas for any reason.\n\n          -  Use of anticholinergic treatment, beta-blocker, alpha-adrenergic or other\n             prescription treatment for hyperhidrosis.\n\n          -  History of diabetes mellitus, thyroid disease, malignancy, glaucoma, intestinal\n             obstructive or motility disease, obstructive uropathy, myasthenia gravis, prostate\n             hypertrophy, neurological conditions or cardiac abnormalities.\n\n          -  Known condition that may cause hyperhidrosis.\n\n          -  Use of an investigational drug within 30 days prior to entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058264", 
            "org_study_id": "BBI-4000-CL-101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Low Strength BBI-4000 and Vehicle", 
                "High Strength BBI-4000 and Vehicle"
            ], 
            "intervention_name": "BBI-4000", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Santo Domingo", 
                    "country": "Dominican Republic"
                }, 
                "name": "Instituto Dermatologico"
            }, 
            "investigator": {
                "last_name": "Daisy Blanco, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Dominican Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.", 
        "overall_contact": {
            "email": "info@brickellbio.com", 
            "last_name": "David Angulo, M.D.", 
            "phone": "786-304-2085"
        }, 
        "overall_official": [
            {
                "affiliation": "Brickell Biotech, Inc.", 
                "last_name": "David Angulo, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Instituto Dermatologico", 
                "last_name": "Daisy Blanco, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Dominican Republic: Ethics Committee"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change in the gravimetrically measured sweat production from baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute change in the gravimetrically measured sweat production from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }
        ], 
        "source": "Brickell Biotech, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brickell Biotech, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}